Cargando…

52例非重型再生障碍性贫血患者环孢素A治疗前后生活质量的变化研究

OBJECTIVE: To explore changes in the quality of life(QoL)in patients with non-severe aplastic anemia(NSAA)after 2 years of cyclosporine A(CsA)therapy, and possible factors may affect the QoL. METHODS: Patients with de novo NSAA from January 2014 to 2016 who had been treated with only CsA for at leas...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656084/
https://www.ncbi.nlm.nih.gov/pubmed/33190436
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.10.003
_version_ 1783608308145324032
collection PubMed
description OBJECTIVE: To explore changes in the quality of life(QoL)in patients with non-severe aplastic anemia(NSAA)after 2 years of cyclosporine A(CsA)therapy, and possible factors may affect the QoL. METHODS: Patients with de novo NSAA from January 2014 to 2016 who had been treated with only CsA for at least 2 years in the outpatient department of Peking Union Medical College Hospital were instructed to fill-in the SF-36 form before and after 2 years of CsA treatment. Data from NSAA were compared with those of normal controls; patients' information such as age, sex, education, annual income, type of payment, and compliance were collected, disease severity and response to treatment were also evaluated. RESULTS: A total of 52 patients were included in our study with 27(51.9%)men and 25(48.1%)women, with the medium age of 48(21–85)years. After 2 years of treatment, 15(28.8%)patients achieved complete response(CR), 25(48.1%)achieved partial response(PR), and 12(23.1%)patients had no response(NR). The overall response rate(ORR)was 76.9%. Before the therapy, SF-36 scores in patients with NSAA were significantly lower than that of normal controls either in physical or mental component summaries(P<0.05). However, after 2 years of therapy, patients with NSAA had significant improvement of mental component summaries and recovered to normal with even higher scores in mental health(MH)(65.9±17.6 vs 59.7±22.9, P=0.014)and energy/vitality(VT)(58.8±20.1 vs 52.3 ± 20.9, P=0.023)compared with normal controls, although they still had comparatively lower scores in physical component summaries. No associations were found between QoL and age, sex, educational level, family income, type of payment, patient adherence, or transfusion dependency. Patients with higher ECOG(the Eastern Cooperative Oncology Group score)at the beginning experienced greater progress in QoL compared to those with lower ECOG. Both patients with CR and PR had shown significant improvement in QoL. CONCLUSION: Patients with NSAA had impaired QoL compared with normal patients. CsA treatment can improve the QoL, especially in mental component summaries. Patients can benefit from the treatment regardless of their social status, and patients with lower ECOG at the beginning seem to benefit more from the therapy.
format Online
Article
Text
id pubmed-7656084
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-76560842020-11-13 52例非重型再生障碍性贫血患者环孢素A治疗前后生活质量的变化研究 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To explore changes in the quality of life(QoL)in patients with non-severe aplastic anemia(NSAA)after 2 years of cyclosporine A(CsA)therapy, and possible factors may affect the QoL. METHODS: Patients with de novo NSAA from January 2014 to 2016 who had been treated with only CsA for at least 2 years in the outpatient department of Peking Union Medical College Hospital were instructed to fill-in the SF-36 form before and after 2 years of CsA treatment. Data from NSAA were compared with those of normal controls; patients' information such as age, sex, education, annual income, type of payment, and compliance were collected, disease severity and response to treatment were also evaluated. RESULTS: A total of 52 patients were included in our study with 27(51.9%)men and 25(48.1%)women, with the medium age of 48(21–85)years. After 2 years of treatment, 15(28.8%)patients achieved complete response(CR), 25(48.1%)achieved partial response(PR), and 12(23.1%)patients had no response(NR). The overall response rate(ORR)was 76.9%. Before the therapy, SF-36 scores in patients with NSAA were significantly lower than that of normal controls either in physical or mental component summaries(P<0.05). However, after 2 years of therapy, patients with NSAA had significant improvement of mental component summaries and recovered to normal with even higher scores in mental health(MH)(65.9±17.6 vs 59.7±22.9, P=0.014)and energy/vitality(VT)(58.8±20.1 vs 52.3 ± 20.9, P=0.023)compared with normal controls, although they still had comparatively lower scores in physical component summaries. No associations were found between QoL and age, sex, educational level, family income, type of payment, patient adherence, or transfusion dependency. Patients with higher ECOG(the Eastern Cooperative Oncology Group score)at the beginning experienced greater progress in QoL compared to those with lower ECOG. Both patients with CR and PR had shown significant improvement in QoL. CONCLUSION: Patients with NSAA had impaired QoL compared with normal patients. CsA treatment can improve the QoL, especially in mental component summaries. Patients can benefit from the treatment regardless of their social status, and patients with lower ECOG at the beginning seem to benefit more from the therapy. Editorial office of Chinese Journal of Hematology 2020-10 /pmc/articles/PMC7656084/ /pubmed/33190436 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.10.003 Text en 2020年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
52例非重型再生障碍性贫血患者环孢素A治疗前后生活质量的变化研究
title 52例非重型再生障碍性贫血患者环孢素A治疗前后生活质量的变化研究
title_full 52例非重型再生障碍性贫血患者环孢素A治疗前后生活质量的变化研究
title_fullStr 52例非重型再生障碍性贫血患者环孢素A治疗前后生活质量的变化研究
title_full_unstemmed 52例非重型再生障碍性贫血患者环孢素A治疗前后生活质量的变化研究
title_short 52例非重型再生障碍性贫血患者环孢素A治疗前后生活质量的变化研究
title_sort 52例非重型再生障碍性贫血患者环孢素a治疗前后生活质量的变化研究
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656084/
https://www.ncbi.nlm.nih.gov/pubmed/33190436
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.10.003
work_keys_str_mv AT 52lìfēizhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhuánbāosùazhìliáoqiánhòushēnghuózhìliàngdebiànhuàyánjiū
AT 52lìfēizhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhuánbāosùazhìliáoqiánhòushēnghuózhìliàngdebiànhuàyánjiū
AT 52lìfēizhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhuánbāosùazhìliáoqiánhòushēnghuózhìliàngdebiànhuàyánjiū
AT 52lìfēizhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhuánbāosùazhìliáoqiánhòushēnghuózhìliàngdebiànhuàyánjiū
AT 52lìfēizhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhuánbāosùazhìliáoqiánhòushēnghuózhìliàngdebiànhuàyánjiū
AT 52lìfēizhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhuánbāosùazhìliáoqiánhòushēnghuózhìliàngdebiànhuàyánjiū
AT 52lìfēizhòngxíngzàishēngzhàngàixìngpínxuèhuànzhěhuánbāosùazhìliáoqiánhòushēnghuózhìliàngdebiànhuàyánjiū